Mesirow Financial Investment Management Inc. Has $195,000 Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Mesirow Financial Investment Management Inc. decreased its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 18.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 10,126 shares of the company’s stock after selling 2,219 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Syndax Pharmaceuticals were worth $195,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of SNDX. Swiss National Bank lifted its position in shares of Syndax Pharmaceuticals by 5.8% in the first quarter. Swiss National Bank now owns 150,600 shares of the company’s stock worth $3,584,000 after purchasing an additional 8,200 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Syndax Pharmaceuticals by 2.5% during the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after buying an additional 991 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Syndax Pharmaceuticals by 29.6% in the 1st quarter. ProShare Advisors LLC now owns 20,112 shares of the company’s stock valued at $479,000 after acquiring an additional 4,599 shares in the last quarter. Vanguard Group Inc. grew its stake in Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after purchasing an additional 591,631 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Syndax Pharmaceuticals by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after purchasing an additional 1,312 shares in the last quarter.

Syndax Pharmaceuticals Trading Down 25.6 %

Shares of NASDAQ SNDX opened at $16.21 on Wednesday. The business’s 50 day moving average is $19.14 and its 200-day moving average is $20.33. The firm has a market cap of $1.38 billion, a P/E ratio of -4.64 and a beta of 0.92. Syndax Pharmaceuticals, Inc. has a 1-year low of $13.14 and a 1-year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the business earned ($0.73) EPS. Analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.61 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. The Goldman Sachs Group raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Bank of America lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Citigroup upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. reduced their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).